Table 5.

Invasive cancer versus screen normals

TrainingValidation
MarkerAUCPaInvertbAUCP
bFGF0.7693.1e−07Yes0.7242.1e−05c
NME20.7598.2e−07Yes0.7722.4e−07c
GLO10.7463.0e−06Yes0.7846.9e−08c
hS100A60.7339.4e−06Yes0.8039.0e−09c
S100A40.7097.0e−05Yes0.7376.9e−06c
CEA0.6970.00020.5830.117
ErbB20.6780.0010.5510.336
MBD10.670.001Yes0.5560.279
E-cadherin0.6690.0010.6250.011c
AKR1B10.6680.001Yes0.6510.004c
Eotaxin0.6660.002Yes0.6260.016c
MCP-40.6660.002Yes0.550.343
ICAM0.6540.0030.6430.007c
CA1250.6510.0040.5890.091
IL1β0.6430.006Yes0.5830.109
GSTM10.640.008Yes0.6190.023
MCP-10.6390.008Yes0.6210.022c
TARC0.6370.009Yes0.6580.003c
GPI0.6370.009Yes0.6450.006c
ODC10.6330.011Yes0.60.057
RAC10.6310.012Yes0.6650.002
IL100.630.0130.5040.933
SERPINB30.6240.018Yes0.5210.693
Osteoprotegerin0.6220.020.5370.483
GSTM20.6220.02Yes0.5880.091
TNFRI0.6190.0240.5830.114
TNFRII0.6160.0270.5540.309
VEGF-C0.6130.031Yes0.6510.004c
LBP0.6120.0330.6970.0002
SAT0.6120.034Yes0.6060.043
IL12p700.6110.0350.5750.152
VEGF0.6080.041Yes0.5850.108
SFN0.6070.042Yes0.5210.697
Eotaxin-30.6040.049Yes0.6260.016
  • aAll markers with unadjusted P values less than 0.05 in the training phase are shown.

  • bIf “yes,” then the values were higher in the controls compared with cases.

  • cAlso significant for benign versus normal.